Introduction
Vaccinia virus (VV) is a poxvirus and has a large doublestranded DNA genome, complex virus particle and cytoplasmic site of replication (Moss, 2001) . The VV genome has been sequenced for strains Copenhagen (Goebel et al., 1990) , Tian Tan (accession no. AF095689), modified virus Ankara (MVA) (Antoine et al., 1998) and most of Western Reserve (WR) and references therein]. These data show that VV encodes approximately 200 genes and those located in the central region are highly conserved, encoding enzymes, transcription factors and structural proteins necessary for virus replication. In contrast, the regions of the genome adjacent to each terminus are more variable and encode genes that are mostly non-essential for virus replication in cell culture (Perkus et al., 1991) but which affect features such as host range, virulence and immunomodulation. Near the right end of the VV WR genome several genes were predicted to encode soluble glycoproteins and some of these proteins showed amino acid similarity to cell proteins that function as receptors for host cytokines or interferons. Gene B15R encodes a soluble receptor for interleukin (IL)-1β (Alcamı! & Smith, 1992 ; Spriggs et al., 1992) , gene B18R encodes a soluble and cell surface receptor for type I interferons (IFN) (Colamonici et al., 1995 ; Symons et al., 1995 ; Alcamı! et al., 2000) and gene B8R encodes a soluble receptor for type II IFN or IFN-γ Mossman et al., 1995) . Gene B8R is the subject of this paper.
IFN-γ is a pleiotropic cytokine that promotes the Th1 immune response and also has direct antiviral activity (Farrar & Schreiber, 1993) . It is a secreted, 17 kDa glycoprotein that binds to the IFN-γR on the surface of cells. This interaction triggers dimerization of the receptor (Fountoulakis et al., 1991 (Fountoulakis et al., , 1992 Greenlund et al., 1993) , leading to signal transduction. The crystal structure of IFN-γ showed that the protein is largely α-helical and exists as a dimer (Ealick et al., 1991 ; Samudzi et al., 1991 ; Walter et al., 1995) . The IFN-γR is an 85-90 kDa glycoprotein with a type I membrane topology, it has 2 fibronectin type III repeats and is a member of the class II cytokine receptor superfamily (Farrar & Schreiber, 1993) . Only a single IFN-γR exists and transgenic mice lacking this protein show an enhanced sensitivity to infection with VV and other viruses (Huang et al., 1993) . Likewise, treating animals with IFN-γ increases their resistance to virus infection (Karupiah et al., 1993 ; van den Broek et al., 1995) .
The VV B8R protein has amino acid similarity to the T7 protein of myxoma virus that binds and inhibits rabbit IFN-γ (Upton et al., 1992) . Subsequently, the VV B8R gene was shown to encode a 43 kDa secreted glycoprotein that inhibits IFN-γ from human, cow, rabbit, rat and chicken but not mouse Mossman et al., 1995 ; Puehler et al., 1998) . The broad species specificity was unexpected because IFN-γ and IFN-γR from cells are largely species-specific. Nonetheless, deletion of the B8R gene from VV was reported to cause virus attenuation in a mouse model (Verardi et al., 2001) . Recently, the VV B8R protein was shown to be a homodimer in the absence of ligand, unlike the cellular IFN-γR that dimerizes upon ligand binding (Alcamı! & Smith, 2002) .
Here we have studied the role of the VV IFN-γR in virus virulence by the construction of WT and deletion viruses and a recombinant virus expressing a soluble form of the mouse IFN-γR. These viruses replicated normally in cell culture but showed differences in vivo.
Methods
Cells and viruses. BS-C-1, RK "$ , HeLa D980R, TK − 143 and Cos-7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10 % foetal bovine serum (FBS). Equine dermal cells were grown in minimal essential medium (MEM) containing 10 % FBS and were obtained from Dr Jay Patel (Akzo Nobel). The Western Reserve (WR) strain of VV was used throughout and was grown, titrated and purified as described (Mackett et al., 1985) . Cocal virus was obtained from Dr W. James (Sir William Dunn School of Pathology, University of Oxford) and Semliki Forest virus (SFV) was obtained from Dr Jay Patel (Akzo Nobel).
Reagents. Radioiodinated human IFN-γ ("#&I-hIFN-γ ; specific activity 50-125 µCi\µg) was obtained from New England Nuclear Life Science Products. Purified recombinant hIFN-γ (3i10( U\mg) was obtained from PeproTech Ltd (London, UK) and recombinant mouse IFN-γ (5i10' U\mg) was obtained from Genzyme and R&D Systems. Equine IFN-γ was obtained by transfection of Cos-7 cells with pCIneo\Eq-IFNγ (a gift from Dr Jay Patel). The supernatant was harvested 5 days later, centrifuged at 10 000 g to remove cellular debris and the equine IFN-γ was titrated as described below. One unit of equine IFN-γ was defined as that which reduced SFV plaque formation by 50 %. Typically Cos-7 supernatants contained approximately 70 U\ml IFN-γ.
Hamster monoclonal antibody (mAb) against the mIFN-γ receptor (alpha chain) was obtained from Genzyme. Biotinylated goat antihamster IgG was obtained from Vector Laboratories and streptavidin-horseradish peroxidase was from Amersham.
Primer extension analysis. RNA was isolated from RK "$ cells that had been mock-infected or infected with VV at 10 p.f.u. per cell for 6 h in the presence or absence of 100 µg\ml cycloheximide or for 16 h in the presence or absence of 40 µg\ml cytosine arabinoside (AraC) as described previously (Ausubel et al., 1990) . Oligonucleotide 5h CTTATA-ACTAGTTATTTTAGCGTGTATAC 3h was labelled at the 5h end with $#P by incubation with [γ-$#P]ATP (10 µCi\ml, 3000 Ci\mM, Amersham) and T4 polynucleotide kinase (New England Biolabs) and hybridized to 10 µg of denatured RNA samples. The nucleotide primer was extended with reverse transcriptase (RNase H − ) (GibcoBRL) and the sample was electrophoresed on a 6 % polyacrylamide gel alongside a $&S-labelled DNA sequencing ladder and detected by autoradiography. Isolation of RNA and preparation of cDNA from EL-4 cells. Total cellular RNA was isolated from the murine thymoma cell line EL-4.NOB1 using RNAzol (Biogenesis Ltd, Poole, UK), following the manufacturer's instructions. Complementary DNA was synthesized using 5 µg of RNA, oligo(dT) and avian myeloblastosis virus reverse transcriptase (Promega).
Construction of recombinant viruses. A virus deletion mutant lacking 96 % of the B8R ORF was constructed using transient dominant selection (Falkner & Moss, 1990) . A plasmid was assembled that contained the DNA flanking the 5h and 3h regions of the B8R ORF. These fragments were amplified by PCR using Pyrococcus furiosus DNA polymerase and VV WR DNA as template. The left flanking region was amplified with oligonucleotides 5h CTAGAATTCAACGCAGAGGTC-ACACG 3h (B8R1F) and 5h ATCCCCGGGTGTTGTTTGTTATTTGAC 3h (B8R1R) that contain EcoRI and SmaI sites, respectively (underlined). The right flanking region was amplified with oligonucleotides 5h CCAGGATCCTTAGCATGCTTAACTTGAC 3h (B8R2F) and 5h TC-AAAGCTTCACTTGCAGTTGGG 3h (B8R2R) that contain BamHI and HindIII sites (underlined), respectively. These fragments were digested with the appropriate restriction enzymes and cloned sequentially into plasmid pSJH7 (Hughes et al., 1991) that had been cut with the same enzymes. The resultant plasmid, termed p∆B8R, contained 319 and 302 nucleotides of the 5h and 3h flanking sequence, respectively, including 30 nucleotides of coding sequence at the 3h end of the gene. The DNA sequence was determined and shown to be correct.
Plasmid p∆B8R was transfected into VV-infected cells and mycophenolic acid (MPA)-resistant recombinant viruses were isolated as described (Falkner & Moss, 1990) . These were grown on hypoxanthine guanine phosphoribosyltransferase-negative D980R cells in the presence of 6-thioguanine (TG) (Kerr & Smith, 1991) and plaque isolates corresponding to WT (vB8R) or deletion mutant (v∆B8R) were identified by PCR using oligonucleotides that span the B8R gene locus.
A revertant virus (vB8R-R) was constructed by transfecting a plasmid (pB8R-R) into v∆B8R-infected cells. This plasmid was constructed by digesting pSTH1 (Engelstad & Smith, 1993) with PstI and SphI and the resulting 1003 bp fragment containing the entire B8R ORF and flanking regions was cloned into p∆B8R that had been cut with the same enzymes. The DNA sequence was determined and shown to be correct. MPAresistant intermediate viruses were isolated as above and resolved into deletion mutant and revertant viruses (vB8R-R) on D980R cells in the presence of 6-TG as described.
A recombinant virus that expressed a soluble version of the mouse IFN-γR (vsmIFN-γR) was constructed as follows. The extracellular domain of the mouse IFN-γR alpha chain (amino acids 1-257) was amplified by PCR with EL-4.NOB1 cDNA as a template using the primers 5h ACAACACCATGGGCCCGCAGGCGGC 3h (IFN-γR\B8R5h) and 5h AAATTAGTTATGAATCCTTTCTGTCATC 3h (IFN-γR\B8R3h). This was fused to the B8R promoter using splicing by overlap extension (Horton et al., 1989) . The 5h and 3h flanking regions of the B8R ORF were amplified by PCR with VV WR DNA as a template using the primers 5h GCCGCCTGCGGGCCCATGGTGTTGTTTGTTATTTG 3h (B8R5h\IFN-γR) and B8R1F (above) and 5h GATGACAGAAAGGATT-CATAACTAATTTTTATTAATGATACAAAAACG 3h (B8R3h\IFN-γR) and B8R2R (above). VV sequences are shown in plain type, mouse IFN-γR alpha chain sequences in bold type and initiation and stop codons are underlined. These three PCR products were reamplified using the B8R1F and B8R2R primers and the assembled DNA fragment was then digested with EcoRI and HindIII and cloned into pSJH7 that had been cut with the same enzymes, to form plasmid pB8R\smIFNγR. DNA sequence analysis showed the sequence was correct.
Plasmid pB8R\smIFNγR was transfected into v∆B8R-infected cells and a virus expressing the soluble murine IFN-γR alpha chain (vsmIFN-γR) under control of the B8R promoter was isolated by transient dominant selection as above. This virus was used to generate a v∆B8R-revertant virus (v∆B8R-R) in which the mouse vIFN-γR gene was removed and the B8R locus was restored to that of the parental virus v∆B8R. Cells infected with vsmIFN-γR were transfected with p∆B8R and the revertant virus was generated by transient dominant selection as above.
Preparation of supernatants from virus-infected cells. TK − 143B cells were infected at 5 p.f.u. per cell. At the indicated times supernatants were harvested and centrifuged at 3000 r.p.m. for 10 min at 4 mC to remove cellular debris. Virus particles were removed by centrifugation at 16 500 r.p.m. in an SW41 Ti rotor for 60 min at 4 mC and the supernatants were stored at k20 mC.
Construction and expression of a B8R-Fc fusion protein.
The VV WR B8R gene fused to the Fc region of human IgG1 was constructed in pCOSFCLINK (a generous gift from Dr Peter R. Young, SmithKline Beecham Pharmaceuticals, King of Prussia, PA, USA). The chimaera was obtained by PCR using VV WR DNA as template and the oligonucleotides 5h GTCGAATTCCAAACAACACCATGAG 3h (EcoRI site, underlined) and 5h ATTGGTACCTGAATATTTAGTCAAG 3h (that inserts a Gly and Thr via a KpnI site, underlined, after amino acid 272 of the B8R protein before the hinge region of human IgG1 that was provided by the pCOSFCLINK plasmid). The resultant plasmid was called pCOS B8R-Fc. The sequence of the B8R gene was confirmed as identical to that reported previously. The plasmid was transfected into DHFR − CHO cells and stable transfectants were selected in increasing concentrations of methotrexate (MTX ; Sigma) up to a final concentration of 10 µM. B8R-Fc fusion protein production was quantified using an ELISA for human IgG1 Fc. CHO cells expressing B8R-Fc fusion protein were adapted to grow in defined medium (CHO-S-SFM II ; GibcoBRL) and the B8R-Fc fusion protein was purified from the supernatant on a protein A-Sepharose column (Pharmacia). Expression of the 35K-Fc fusion protein has been described .
Biological assays for IFN. The biological activity of hIFN-γ was measured by the inhibition of cocal virus plaque formation as described . The biological activity of equine IFN-γ was measured by the inhibition of SFV plaque formation on equine dermal cells. Cells were pretreated with 10 U of equine IFN-γ for 24 h. The cells were then infected with 100 p.f.u. of SFV and plaques were stained and counted 48 h p.i.
Binding assays. Covalent cross-linking of "#&I-hIFNγ to supernatants from VV-infected cells was performed as described .
BIAcore analysis. Surface plasmon resonance (SPR) experiments used a BIAcore 2000 (BIAcore, St. Albans, UK) (Nicholson et al., 1998) . The purified mAb R10ZD9 (anti-human IgGFc ; a gift from Dr P. Anton van der Merwe) was immobilized to CM5 sensor chips (BIAcore) using the Amine Coupling Kit (BIAcore) with a flow rate of 10 µl\min.
Immobilized R10ZD9 was regenerated with no loss of IgGFc binding by sequential injections of 10 mM NaOH and 0n1 M glycine, pH 2n5. B8R-Fc and 35K-Fc (control) fusion proteins were coupled by injection at 30 µg\ml for 10 min at a flow rate of 5 µl\min. For kinetic experiments, mouse and human IFN-γ were injected in 50 µl at 50 µl\min at various concentrations between 100 pM and 1n0 µM. Kinetic constants were derived using the curve-fitting facility of the BIAevaluation program (version 3.0, BIAcore) using a simple 1 : 1 binding model. To correct for refractive index changes, binding responses generated in the control surface (35K-Fc) were subtracted from responses generated in the B8R-Fc surface.
Ligand blotting. Proteins from supernatants from VV-or baculovirus-infected cells and purified Fc fusion proteins were resolved by SDS-PAGE under non-reducing conditions on a 10 % gel and transferred onto 0n45 µM nitrocellulose (Schleicher and Schuell). The filters were blocked in 3 % (w\v) non-fat skimmed milk in 10 mM Tris-HCl (pH 7n4), 140 mM NaCl, 0n02 % (w\v) NaN $ overnight at 4 mC, and then probed with 5 ng\ml "#&I-hIFN-γ in blocking buffer with or without 1 mg\ml cold IFN-γ for 4 h at room temperature. Blots were then washed, dried in air and exposed to X-ray film.
Immunoblotting for mouse IFN-γR alpha chain. Virus-free supernatants from 6i10% cells were resolved by SDS-PAGE under nonreducing conditions on a 12n5 % polyacrylamide gel and transferred onto nitrocellulose (Hybond-ECL ; Amersham). After blocking in 5 % (w\v) nonfat skimmed milk in PBS-0n1 % (v\v) Tween 20, the membrane was incubated sequentially with a hamster mAb against mouse IFN-γR alpha chain (Genzyme) at 1 µg\ml, biotinylated anti-hamster IgG conjugate (Vector Laboratories) at 1n5 µg\ml, and finally streptavidin-horseradish peroxidase conjugate (1 : 1500 ; Amersham). Immunoreactive bands were visualized by enhanced chemiluminescence.
Assays of viral virulence. Intranasal infection of female, BALB\c mice (5-6 weeks old) was performed as described (Symons et al., 1995) . Each day, mice were weighed individually and monitored for signs of illness. Those having lost 30 % of their initial body weight were sacrificed.
For intradermal infection, 10% p.f.u. of recombinant VV in 10 µl of PBS was injected into the ear pinnae of female BALB\c mice between 8 and 12 weeks of age. The diameter of lesions was measured daily as described (Tscharke & Smith, 1999) .
Female New Zealand White rabbits (1n5 kg) were injected intradermally with 10%, 10& or 10' p.f.u. of the indicated viruses\site in 0n1 ml of PBS along the flanks of the animal. Animals were monitored daily for signs of illness and the lesion size was measured with fine calipers. At 3 and 5 days p.i. animals were sacrificed and lesions excised for immunohistochemical analysis.
Immunohistochemistry. Rabbit dermal samples were prepared and immunostained using anti-rabbit CD43 antibody (IgG1 ; Serotec) to detect rabbit T cells, monocytes and macrophages, or mouse mAb 5B4\2F2 against the VV A27L protein (Czerny & Mahnel, 1990) as described previously (Ng et al., 2001) . Sections were counterstained with 0n1% (w\v) cresyl violet acetate, dehydrated, mounted and examined as described previously (Ng et al., 2001) . Several 10 µm sections were examined to ensure that those shown are representative.
Results
The 5h end of the B8R mRNA was mapped by primer extension analysis (Fig. 1a ). An oligonucleotide complementary to the B8R mRNA (Fig. 1b) was labelled with $#P at its 5h end and hybridized to RNA extracted from VV-infected cells that had been incubated with or without cycloheximide or AraC (an inhibitor of virus DNA replication and therefore of intermediate and late gene expression). Reverse transcription products were analysed alongside a sequencing ladder (Fig. 1a) . A major product of 96 nucleotides and a minor product of 95 nucleotides were obtained using RNA extracted from cells infected for 6 h in the presence of cycloheximide (lane 2), but not with RNA from mock-infected cells or from cells infected for 6 h in the absence of cycloheximide or for 16 h in the presence or absence of AraC. The presence of B8R RNA 6 h p.i. in only the presence of cycloheximide is consistent with the build up of early transcripts in the absence of protein synthesis. These data indicate that the B8R gene is transcribed early during infection predominantly from a site 27 nucleotides upstream of the initiating methionine codon of the B8R ORF. This RNA start site is approximately 14 bp downstream of a motif, 5h AAAAATTTAAAATATA 3h, that is similar to the consensus sequence for this region of early VV promoters (Davison & Moss, 1989) .
Construction of deletion and revertant viruses
The role of the B8R gene in VV replication in vitro and in vivo was investigated using WT (vB8R), deletion mutant (v∆B8R) and revertant (vB8R-R) viruses. The relative contributions of the VV IFN-γR and soluble mouse IFN-γR to VV virulence in mice was compared by constructing a recombinant virus (vsmIFN-γR) that expressed the mouse IFN-γR alpha chain truncated after Ser-257 so that it would be secreted from the cell. The vsmIFN-γR was compared with parental (v∆B8R) and revertant (v∆B8R-R) viruses.
The genomes of these five viruses were analysed by Southern blot analysis (see supplementary data 1 at JGV Online : http :\\vir.sgmjournals.org). This showed that the genomes of the recombinant viruses were as predicted.
Growth properties of the recombinant viruses in vitro
The plaque phenotype of all viruses was normal on BS-C-1 cells (data not shown). However, this analysis might not detect minor differences in virus replication and therefore the growth properties were investigated after infection of BS-C-1 cells at 0n01 p.f.u. per cell. Over a 48 h period the rate of increase in virus titre and the final titre attained were indistinguishable for all viruses (Fig. 2) .
Expression of IFN-γRs by recombinant viruses
The ability of the viruses to express soluble proteins that bound IFN-γ was measured by ligand blotting and bioassay. First, proteins in the supernatants of mock-infected cells or cells infected with vB8R, v∆B8R and vB8R-R were tested for binding to human IFN-γ by cross-linking with EDC followed by SDS-PAGE and autoradiography. vB8R and vB8R-R expressed a protein that cross-linked with human IFN-γ and the formation of this complex was inhibited by a 100-fold excess of cold human IFN-γ but not IFN-α (data not shown). In contrast, v∆B8R did not express this protein, confirming that B8R was the only VV gene encoding such an activity.
The expression of soluble mouse IFN-γR by vsmIFN-γR was demonstrated by bioassay (Fig. 3a) . Mouse IFN-γ prevented the formation of plaques by cocal virus on mouse L929 cells and this activity was inhibited in a dose-dependent manner by the supernatants from cells infected with vsmIFN-γR but not by those from WR-or v∆B8R-infected cells. This showed that vsmIFN-γR expressed a soluble protein that inhibited mouse IFN-γ and confirmed that the IFN-γR made by VV WR does not inhibit mouse IFN-γ. Immunoblotting with a mAb specific for the mouse IFN-γR alpha chain confirmed expression of the mouse soluble IFN-γR (38-40 kDa) (Fig. 3b) .
The mouse IFN-γR gene was expressed from the VV B8R promoter to mimic the temporal regulation of the B8R gene. Early expression was confirmed by infecting cells with vsmIFN-γR with or without AraC and observing similar levels of protein.
Expression of B8R as an Fc-fusion protein
To produce recombinant B8R protein from a mammalian source, the B8R protein was fused to the Fc domain of human IgG1 and expressed from transfected COS cells using methodology described previously for the CC chemokine-binding protein of VV strain Lister . Supernatants from cells transfected with B8R-Fc, or from mammalian cells infected with WR or v∆B8R, or from Sf21 insect cells infected with a recombinant baculovirus that expresses the VV IFN-γR, AcB8R , were analysed by ligand blotting after electrophoresis in the absence of reducing agent (Fig. 4a) . Cells infected with VV WR, but not v∆B8R, expressed an 85-90 kDa protein, consistent with the B8R protein existing as a homodimer (Alcamı! & Smith, 2002) . The size of the VV IFN-γR made by insect cells (" 67 kDa) or as a B8R-Fc fusion (nearly 200 kDa) also indicated B8R was a homodimer. The specificity of each protein for IFN-γ was demonstrated by the inhibition of binding with a 100-fold excess of cold IFN-γ. The biological activity of purified B8R-Fc was demonstrated by its ability to inhibit the activity of human IFN-γ in a dosedependent manner (Fig. 4b) . Equivalent concentrations of 35K-Fc had no such inhibitory activity.
Affinity of B8R for human and mouse IFN-γ
The affinity of B8R for human and mouse IFN-γ was determined by surface plasmon resonance using BIAcore. B8R-Fc was bound to the surface of the sensor chip via the Fc domain that was recognized by an anti-Fc mAb. Different concentrations of human or mouse IFN-γ were then passed across the chip surface and the association, dissociation and K d values were calculated from the association and dissociation kinetics. Although the association rates for human and mouse IFN-γ (5i10' and 1i10' mol\s, respectively) differed by only 5-fold, the dissociation rate for human IFN-γ (4n3i 10 −% mol\s) was approximately 100-fold slower than for mouse IFN-γ (4i10 −# mol\s). Consequently, B8R had a much higher affinity constant (9i10 −"" M) for human IFN-γ than mouse IFN-γ (4i10 −) M) and this was consistent with the ability of B8R to inhibit human but not mouse IFN-γ in bioassay .
Contribution of B8R and mouse soluble IFN-γR in vivo
Although the B8R protein was dispensable for virus replication in cell culture it was likely to play a role in vivo and this was tested in three models. In a mouse intranasal infection model the mortalities (data not shown), weight loss (Fig. 5a ) and signs of illness (not shown) of vB8R, v∆B8R and vB8R-R were not statistically different (P 0n05, Student's t-test) from each other on any day following infection with 10% or 10& p.f.u. Similarly, in a murine intradermal model (Tscharke & Smith, 1999 ) the resultant lesion size was indistinguishable for all three viruses (Fig. 5b) . These results were consistent with the low affinity of the VV vIFN-γR for mouse IFN-γ and its inability to inhibit the biological activity of mouse IFN-γ in vitro.
Next the role of the VV IFN-γR was examined in a rabbit intradermal model, because the virus protein is known to inhibit the biological activity of the rabbit IFN-γ. At 3 days p.i. with 10' p.f.u. the lesions were examined histologically (Fig.  6) . Infection with v∆B8R caused a greater infiltration of CD43 + inflammatory cells than infection with WT or revertant viruses, although changes in lesion sizes were not apparent. Conversely, the level of VV antigen as measured using a mAb to the A27L gene product showed that after infection with v∆B8R there was a reduced level of VV antigen in the dermis.
To study the contribution of a soluble IFN-γR to VV virulence in a mouse model we constructed a recombinant Fig. 6 . Histological analysis of infected rabbit skin. New Zealand White rabbits were infected with the indicated viruses and at 3 days p.i. were sacrificed and the lesion was processed for immunohistochemistry using antibodies against rabbit CD43 (α-CD43) and against the VV A27L gene product (α-A27L) as described in Methods.
virus expressing the soluble mouse IFN-γR from the B8R locus under control of the B8R promoter. After intranasal infection, vsmIFN-γR was more virulent than v∆B8R and v∆B8R-R control viruses. On days 4, 5, 6 and 8 p.i. with 10% p.f.u. there was a statistically significant (P 0n05, Student's t-test) greater weight loss following infection with vsmIFN-γR than with each control virus (Fig. 7a) . Furthermore, after infection with 10% or 10& p.f.u. the signs of illness (Alcamı! & Smith, 1992) appeared sooner and were more severe with significant differences from controls on days 4, 5, 6 and 7 p.i. with each dose. In the intradermal mouse model, there was a slight reduction in mean lesion size after infection with vsmIFN-γR compared to controls but this difference was not statistically significant (Fig. 7b) .
Inhibition of equine IFN-γ
Finally, we tested the ability of the VV IFN-γR to inhibit equine IFN-γ. Data presented show that the supernatants from cells infected with VV strain WR, but not v∆B8R, possess an activity that inhibits the biological activity of equine IFN-γ in a dose-dependent manner as measured by the reversal of the inhibition of SFV plaque formation by equine IFN-γ on equine dermal cells (Fig. 8) . The VV IFN-γR has now been demonstrated to inhibit IFN-γ from man, cow, rat, rabbit, horse and chicken but not mouse.
Discussion
This report provides a further characterization of VV gene B8R gene and the encoded vIFN-γR including the contribution of this protein to virus virulence. Data presented demonstrate that gene B8R is transcribed early during infection, is nonessential for virus replication in cell culture and is the only VV WR gene encoding an IFN-γR. The range of IFN-γs that the VV IFN-γR inhibits is extended to include equine IFN-γ and the affinity constants of the B8R protein for human and mouse IFN-γ were determined. In vivo, the VV B8R protein did not affect virulence in mouse models, but affected the outcome of infection in rabbit skin. In contrast, a recombinant VV expressing mouse soluble IFN-γ had enhanced virulence compared to controls in the murine intranasal model. Previously, the VV B8R protein was shown to inhibit IFN-γ from a wide range of species, although it distinguished between the closely related mouse and rat IFN-γ. Here the range of IFN-γs that B8R inhibits is extended to equine IFN-γ. The rationale for investigating equine IFN-γ was that early vaccinators took material from horses and used this for smallpox vaccination when cowpox virus was scarce. In addition the Ankara strain of VV, from which MVA was derived, was isolated from a horse in Turkey. This prompted Baxby (1981) to suggest that the unknown host of VV might be horses. If this is true, then the terms vaccinia, vaccine and vaccination might have been equinia, equine and equination! The K d for human and mouse IFN-γ was determined. As expected from the biological inhibition of human but not mouse IFN-γ, the B8R protein had a much higher affinity for human than mouse IFN-γ. The K d for human IFN-γ (9i 10 −"" M) compares favourably with the affinity of human and mouse IFN-γR for their ligands (10 −"" -10 −"! M) (Aguet et al., 1988 ; Hemmi et al., 1989) thus explaining the ability of B8R to block the biological activity of human IFN-γ. In contrast, the affinity of B8R for mouse IFN-γ (4i10 −) M) is unlikely to be high enough to compete with the natural mouse cell surface receptor. The affinity of the soluble IFN-γR α chain is lower than that of the cell surface receptor (K d l 10 −* M) (Walter et al., 1995) . This is consistent with the finding that although the IFN-γR beta chain does not form an independent binding site for IFN-γ, it does contribute to the binding affinity for IFN-γ.
The low affinity for mouse IFN-γ was consistent with the lack of virus attenuation in two mouse models after deletion of the B8R gene. In contrast, in a rabbit model there was an increase in infiltration of CD43 + leukocytes after infection with the deletion mutant compared to controls. This enhanced infiltration was accompanied by a corresponding decrease in the level of VV antigen. Our study has a different conclusion to another paper that reported that disruption of B8R reduced VV strain WR virulence after intranasal infection of CB6F " mice or intraperitoneal injection of nude mice (Verardi et al., 2001) . Possible reasons for this discrepancy are that different mouse strains were utilized, or that the insertion of strong, bidirectional, synthetic VV promoters and the β-galactosidase gene into the B8R locus affected virulence, or that the deletion mutants described by Verardi et al. contained an additional mutation that contributed to the attenuated phenotype. The latter possibility was not addressed by the construction of revertant viruses.
To study the contribution of an IFN-γR in a mouse model, we constructed a virus that expresses the mouse IFN-γR. To make the situation as analogous as possible to the VV B8R protein, the mouse IFN-γR gene was expressed from the B8R promoter and was truncated before the region encoding the transmembrane anchor so that the protein was secreted from the cell. However, one difference between the mouse soluble IFN-γR and the VV IFN-γR is the ability of the latter protein to dimerize in the absence of IFN-γ (Alcamı! & Smith, 2002) . This property may give the VV protein enhanced ability to neutralize IFN-γ. The secreted smIFN-γR inhibited the biological activity of the mouse IFN-γ and the recombinant virus expressing this protein had enhanced virulence in a mouse model. The changes in vivo observed by either insertion of mouse soluble IFN-γR (in the mouse model) or deletion of VV B8R (in the rabbit model) were modest compared to changes in virulence resulting from the deletion of genes encoding proteins affecting the egress of virus from infected cells, such as A34R (McIntosh & Smith, 1996) , A36R (Parkinson & Smith, 1994) and F12L (Zhang et al., 2000) , but were similar to changes resulting from deletion of other immunomodulators (Moore & Smith, 1992 ; Alcamı! & Smith, 1996) .
The B8R protein affects the outcome of infection in rabbits but not in mice and deletion of the gene would be predicted to be an attenuating mutation in other species in which the host IFN-γ was inhibited by the VV protein. Consistent with this, VV MVA does not make an IFN-γR (Blanchard et al., 1998) and is attenuated in man compared to other VV strains, although the contribution of B8R to this phenotype has not been determined. It will be interesting to examine the immune response to infection with viruses lacking the B8R protein (in rats or rabbits) or containing the mouse IFN-γR (in mice).
In conclusion, the VV B8R protein is shown to be a nonessential immunomodulator that affects virus virulence in a rabbit but not mouse model of infection. The K d values of the B8R protein are consistent with the observed inhibition of human but not mouse IFN-γ by this protein.
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